DROXIDOPA

Bezeichnung:DROXIDOPA

CAS-Nr23651-95-8

Englisch Name:DROXIDOPA

CBNumberCB1699324

SummenformelC9H11NO5

Molgewicht213.19

MOL-Datei23651-95-8.mol

DROXIDOPA physikalisch-chemischer Eigenschaften

Schmelzpunkt	232-235° (dec); mp 229-232° (dec) (Ohashi)
alpha	D20 -39° (c = 1 in 1N aq HCl); D20 -42.0° (c = 1 in 1N aq HCl)
Siedepunkt	549.8±50.0 °C(Predicted)
Dichte	1.608±0.06 g/cm3(Predicted)
storage temp.	-20°C
Löslichkeit	DMSO: ≥3mg/mL
pka	2.09±0.24(Predicted)
Aggregatzustand	powder
Farbe	white to tan
Merck	14,3457
Stabilität	Hygroscopic
CAS Datenbank	23651-95-8

Sicherheit

Kennzeichnung gefährlicher	Xi
R-Sätze:	36/37/38
S-Sätze:	26
WGK Germany	3
RTECS-Nr.	VT9626010
HS Code	29225090

Gefahreninformationscode (GHS)

DROXIDOPA Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Droxidopa is a synthetic amino acid precursor of (-)-norepinephrine which is absorbed from the gut and metabolized to norepinephrine. In Parkinsonian patients, droxidopa added to existing levodopa/decarboxylase inhibitor therapy produces significant improvements in retropulsion, dysarthria and muscular rigidity refractory to other treatments; however, tremor was unaffected.
Beschreibung
Droxidopa (L-DOPS) is a synthetic precursor and prodrug of the neurotransmitter norepinephrine. It is transformed into norepinephrine through the action of DOPA decarboxylase. L-DOPS increases norepinephrine levels in the rat heart following intraperitoneal administration and in the brain following intracerebroventricular administration at doses of 125 and 100 μg/animal, respectively. It increases arterial pressure and mesenteric arterial resistance in rats with ligated portal vein or biliary ducts when used at doses of 25-50 mg/kg. L-DOPS crosses the blood brain barrier, however, its effects can be blocked by the peripherally-restricted DOPA decarboxylase inhibitor carbidopa , indicating that the mechanism is peripheral. Formulations containing droxidopa are used in the treatment of neurogenic orthostatic hypotension.
Chemische Eigenschaften
Off-White Solid
Originator
Sumitomo (Japan)
Verwenden
Droxidopa is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).
Verwenden
The L-threo-form Droxidopa. A synthetic amino acid precursor of Norepinephrine (N674500). Antiparkinsonian.
Verwenden
L-DOPS has been administered for clinical trial studies in mice with amyloid pathology.
Definition
ChEBI: A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension
Trademarks
DOPS
Allgemeine Beschreibung
L-DOPS, also called L-threo 3,4-Dihydroxyphenylserine or droxidopa is a catecholamine. L-DOPS has many clinical advantages and may be useful for treating norepinephrine deficiency. It is used for treating neurogenic orthostatic hypotension and improves norepinephrine levels. L-DOPS mediates reduction of amyloid plaques and could have a therapeutic potential for treating amyloid pathology.
Biochem/physiol Actions
L-DOPS is a norepinephrine precursor in vivo.

DROXIDOPA Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

23651-95-8, DROXIDOPA Verwandte Suche:

Send Inquriy